ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced its operational and financial results for the year ended December 31, 2019.
March 18, 2020
· 9 min read